Document is current
Any future updates will be listed below
-
Authors
Mahamat-Saleh, Yahya
Merdas, Mira
Viallon, Vivian
Robinot, Nivonirina
Biessy, Carine
Amiano, Pilar
van Gils, Carla
Freisling, Heinz
Bendinelli, Benedetta
Panico, Salvatore
Tumino, Rosario
Eichelmann, Fabian
Schulze, Matthias B.
Sacerdote, Carlotta
Aizpurua, Amaia
Guevara, Marcela
Colorado-Yohar, Sandra M.
Naudin, Sabine
Truong, Thérèse
Zamora-Ros, Raul
Le Cornet, Charlotte
Fortner, Renée Turzanski
Petrova, Dafina
Rinaldi, Sabina
Weiderpass, Elisabete
Severi, Gianluca
Gunter, Marc J.
Keski-Rahkonen, Pekka
Dossus, Laure
-
Funding
Funding for this research was provided by:
The French National Cancer Institute (INCa 15121)
The French National Cancer Institute (INCa 15121)
The Fondation ARC pour la recherche sur le cancer (ARCPOST-DOC2021080004105)
- License Information
-
More Information
Article History
Received: 24 November 2025
Accepted: 26 July 2026
First Online: 11 August 2026
Declarations
Ethics approval and consent to participate: The EPIC study was conducted in accordance with the Declaration of Helsinki. The study was approved by the local ethical committees in participating countries and the IARC ethical committee. All participants provided written informed consent for data collection and storage, as well as individual follow-up before study entry. This study is listed at clinicaltrials.gov as NCT03285230.
Consent for publication: Not applicable.
IARC Disclaimer: Where authors are identified as personnel of the International Agency for Research on Cancer/World Health Organization, the authors alone are responsible for the views expressed in this article and they do not necessarily represent the decisions, policy, or views of the International Agency for Research on Cancer/World Health Organization.
Competing interests: The authors declare no competing interests.
